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Tricin, a flavone found in rice bran, inhibits the growth of human-derived malignant MDA-MB-468 breast tumour cells at
submicromolar concentrations. As part of the exploration of tricin as a potential cancer chemopreventive agent, we investigated the
duration and cell cycle specificity of growth inhibition elicited by tricin in vitro and the effect of tricin on the development of MDA-MB-
468 tumours grown in immune-compromised MF-1 mice in vivo. Preincubation of MDA-MB-468 cells with tricin (1–40mM) for 72h
compromised cell growth after tricin removal, and such irreversibility was not observed in human breast-derived nonmalignant HBL-
100 cells. Tricin (X5mM) arrested MDA-MB-468 cells in the G2/M phase of the cell cycle without inducing apoptosis as adjudged by
annexin V staining. In nude mice consumption of tricin with the diet (0.2%, ww
 1) from 1 week prior to MDA-MB-468 cell
implantation failed to impede tumour development. Steady-state levels of tricin in plasma, breast tumour tissue and intestinal mucosa,
as measured by HPLC, were 0.13mM and 0.11 and 63nmolg
 1, respectively. Cells were exposed to tricin (0.11, 1.1 or 11mM) in vitro
for 72h and then implanted into mice. The volume of tumours in animals bearing cells pre-exposed to 11mM tricin was less than a
third of that in mice with control cells, while tumours from cells incubated with 0.1 or 1.1mM tricin were indistinguishable from
controls. These results suggest that the potent breast tumour cell growth-inhibitory activity of tricin in vitro does not directly translate
into activity in the nude mouse bearing the MDA MB-468 tumour. While the results do not support the notion that tricin is a
promising candidate for breast cancer chemoprevention, its high levels in the gastrointestinal tract after dietary intake render
exploration of its ability to prevent colorectal carcinogenesis propitious.
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One of the perceived health benefits derived from consumption of
cereal foods is their putative ability to prevent cancer (Jacobs et al,
1995; Kasum et al, 2002). Ingestion of whole grains and grain
products has been shown in epidemiological studies to be
associated with a reduced risk of cancers of the breast (Nicodemus
et al, 2001), colon (Smigel, 1992) and prostate (Jain et al, 1999).
Rice, predominantly the unpolished brown (bran-containing)
variety, is a staple cereal food in Asia, where the incidence of
cancer of the breast, colon and prostate is considerably lower than
in Western countries. An extract of rice bran, which had
undergone fermentation by Aspergillus oryzae, was shown to
inhibit the formation of azoxymethane-induced aberrant crypt foci
and tumours in rats (Katyana et al, 2002), consistent with a link
between brown rice consumption and reduced cancer incidence.
Recently, an attempt was made to characterise potential cancer
chemopreventive properties of rice bran ingredients (Hudson et al,
2000). Among potentially pharmacologically active agents identi-
fied was the flavone tricin (40,5,7-trihydroxy-30,50-dimethoxyfla-
vone, for structure see Figure 1). Tricin occurs as a glucoside in
rice bran and other grass species such as wheat, barley and maize.
It interfered potently with the growth of human-derived malignant
MDA-MB-468 breast cancer cells, and was much less growth-
inhibitory in HBL-100 cells, nonmalignant but transformed human
breast cells (Hudson et al, 2000). In 1981 tricin was characterised
in the plant Wikstroemia indica as a constituent with antileukemic
properties in rodents (Lee et al, 1981). It needs to be pointed out
though that the potential contribution of dietary tricin to the low
incidence of cancer of the breast, colon or prostate in Asia as
compared to the West is difficult to reconcile with its occurrence in
cereal grains such as wheat, corn and barley, which are consumed
in large amounts in the West. There is virtually no information
available on the mechanisms via which tricin may exert cancer cell
growth arrest. Flavonoids such as tricin are common in the plant
kingdom, and several of them are considered to possess cancer
chemopreventive efficacy. Thus, their pharmacological mechan-
isms are subject to much current research. The anticarcinogenic
activity of flavonoids has been linked to antioxidation, because
they are polyphenols with a high propensity to undergo redox
reactions and to scavenge oxygen radical species (Rice-Evans et al,
1996; Mitchell et al, 1998; Havsteen, 2002). Other mechanisms that
have been discussed include inhibition of the metabolic activation
of carcinogens (Le Marchand, 2002), induction of enzymes that
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sdetoxify carcinogens (Talalay et al, 1995; Le Marchand, 2002) and
anti-inflammation mediated via inhibition of cyclooxygenase or
lipoxygenase enzymes or inhibition of inducible nitric oxide
synthase (Raso et al, 2001). Furthermore, cellular signalling
pathways, which regulate the cell cycle machinery and thus
influence cell survival/proliferation and promotion and progres-
sion of malignant cells, are pharmacological targets of many
flavonoids (Manson, 2003), exemplified by quercetin contained in
onions and wine, genistein in soya and apigenin in leafy vegetables
and fruits.
In the light of the exquisite sensitivity of human-derived MDA-
MB-468 breast cancer cells towards the growth-inhibitory proper-
ties of tricin (Hudson et al, 2000), we wished to characterise the
effect of tricin on breast cancer cells further, with the ultimate aim
of exploring its chemopreventive potential. The following three
hypotheses were tested: (i) tricin-induced cell growth inhibition is
irreversible, that is, on incubation of cells in culture with tricin and
its subsequent removal, cellular growth potential continues to be
compromised; (ii) the growth-inhibitory activity of tricin is
associated with a selective effect on the cell cycle, engendering
increased apoptosis, and (iii) dietary administration of tricin to
immune-compromised mice bearing the MDA-MB-468 tumour,
which is sensitive to tricin in vitro, achieves target tissue levels
sufficient to compromise tumour development in vivo. As we
found that tricin in the diet (0.2%) had only a slight effect on
tumour formation in vivo, an additional question was addressed as
to whether growth arrest observed in cells exposed to tricin in vitro
translates into reduced tumour development in vivo using an in
vitro–in vivo bioassay. This experimental paradigm entails
exposure of cells to tricin in vitro prior to subcutaneous
implantation into mice, and assessment of the ability of the cells
to develop into full-blown tumours in vivo. Overall, the work was
designed to contribute to the database, which will eventually help
to decide whether tricin is worthy of clinical development as a
breast cancer chemopreventive agent.
METHODS
Chemicals
Tricin, kindly provided by Dr Izet Kapetanovic (Chemoprevention
Agent Development Research Group, NCI Division of Cancer
Prevention, Bethesda, MD, USA), was dissolved in DMSO to
furnish solutions of 25mM (for use in cell culture) and 0.1mgml
 1
(for use in chemical analysis). Quercetin, which was used as
internal standard in the HPLC analysis, RPMI-1640, DMEM, foetal
bovine serum, Glutamax, and RNase A were purchased from
Sigma-Aldrich Comp. Ltd. (Poole, UK). Fluorescein-isothiocya-
nate-conjugated annexin V was bought from Bender MedSystem
(Vienna, Austria). Ammonium acetate, acetic acid, disodium
ethylenediamine-tetraacetic acid (EDTA), and sodium dodecyl
sulphate (SDS) were all of analytical grade (Sigma). HPLC-grade
methanol was obtained from Fisher Chemicals Comp. (Loughbor-
ough, UK), HPLC-grade water was generated in-house in a Nano-
Pure water purification system (Barnstead, UK).
Cell culture and treatments
Human-derived MDA-MB-468 breast cancer cells, originally
obtained from the American Type Culture Collection (Rockville,
MD, USA), were cultured routinely in RPMI 1640, supplemented
with 10% FCS and 2mM Glutamax; human-derived HBL-100 breast
cells, kindly provided by Professor R Walker (Department of
Cancer Studies, University of Leicester) were cultured in DMEM,
supplemented with 10% FCS. Details of growth conditions for both
cell types have been described by Hudson et al (2000). Cells were
cultured in a humidified atmosphere (95% air 5% CO2,3 7 1C). To
aid with the interpretation of the cell growth data described below,
it is important to note that the doubling times of the two cells were
similar, 29 and 32h for MDA-MB 468 and HBL 100 cells,
respectively. Tricin stock solution was diluted with medium to
the desired concentrations, so that the final DMSO content in
culture medium was never greater than 0.2% (vv
 1), which on its
own did not affect cell-growth and cell-cycle distribution. Cells
(seeded at 1 10
4 per well, 12-well plates) were kept for 24h to
allow attachment to the substratum, after which tricin was added.
After periods of up to 168h cells were harvested (trypsinisation)
and counted using a ZM model Coulter Counter (Beckman
Coulter, Luton, UK). IC50 values were computed using plots of
cell number (expressed as a percentage of control) vs tricin
concentration.
To determine the ability of cells to recover following exposure to
tricin, cells were treated for 72h with tricin (1–40mM), after which
they were maintained in fresh medium omitting tricin for a further
96h. The ability of cells to recover following treatment was
calculated as fold increase in cell number over that observed at
72h. For comparison cultures were included in which treatment
with tricin was continued for the whole 168h period.
Flow cytometric cell cycle analysis and assessment of
apoptosis
Asynchronously growing cells were exposed to tricin (1–40mM)o r
vehicle control only for 24, 48, 72 or 96h and harvested. For cell
cycle analysis, cells were centrifuged, washed (phosphate-buffered
saline, PBS) and fixed in ethanol (70%, 41C, 12h). Cells were
centrifuged (600 g, 10min), and the pellet was resuspended and
kept (41C, 12h) in PBS (1ml) containing RNase (0.1mg) and
propidium iodide (PI, 5mg). Flow cytometric analysis was
performed with a Becton Dickinson FACScan (Becton Dickinson
UK Ltd, Cowley, UK). Cell cycle compartments were integrated
using the ModFit LT software (Becton Dickinson). To distinguish
apoptosis from necrosis, cells were treated as above, harvested,
washed in PBS and resuspended in medium and incubated for
30min (371C). Cells were spun down and suspended in annexin V-
staining buffer (1ml). Cell suspension to which FITC-annexin V
had been added was kept for 8min (room temperature), after
which PI was added and the mixture was incubated (2min).
Samples were analysed by flow cytometry using the CellQuest
software (Becton Dickinson). For each sample the number of total
events acquired and gated for analysis was 5000.
Inoculation of MDA-MB-468 cells into mice and evaluation
of the effect of tricin
Female MF1 athymic nude mice (purchased from Harlan, UK)
were maintained under sterile and standard environmental
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Figure 1 Chemical structure of tricin, 40,5,7-trihydroxy-30,50-dimethoxy-
flavone.
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sconditions and used when they were 6–8 weeks of age. Animal
experiments were carried out under a project license granted to
Leicester University by the UK Home Office. The experimental
design was vetted by the Leicester University Local Ethical
Committee for Animal Experimentation and meets the standards
required by the UKCCCR guidelines (Workman et al, 1998). Tricin
was thoroughly mixed with RM1 powdered diet, and the mixture
was kept at 41C for up to 1 month. Diet in food hoppers was
replaced once weekly. Groups of 12 mice each received either
control diet (RM1) or RM1 diet supplemented with 0.2% tricin
(ww
 1) commencing 1 week before tumour inoculation. MDA-
MB-468 cells (10
7) suspended in Leibovitz medium (0.1ml) were
injected subcutaneously into the right flank. For the in vitro–in
vivo bioassay, cells were exposed to tricin 0.11, 1.1 or 11mM (or the
vehicle only) for 72h, after which remaining adherent cells were
harvested. Yields of adherent cells at the three different tricin
concentrations were 100, 81 and 62%, respectively, of vehicle
controls. An aliquot of the cell suspension (5 10
6 cells) was then
injected into mice. Body weights were checked weekly. Tumours
were palpable 1 week after cell inoculation. Tumour size was
assessed by calliper, and tumour volume was calculated by the
formula:
length width
2=2;
where length is the larger and width the smaller diameter of the
tumour (in mm).
Tumour tissue was fixed in neutral buffered formalin and
embedded in paraffin wax. Conventional histological sections,
5mm thick, were cut and stained with haematoxylin and eosin.
HPLC analysis of tricin in cellular incubates and mouse
plasma and tissues
Cells (0.5 10
6 per 10cm plate) were incubated with tricin, an
aliquot of the medium (2ml) was collected, and cells were
harvested. The cell pellet was washed (PBS) and resuspended in
water. At the end of the experiment mice were killed (cardiac
exsanguination) under terminal anaesthesia with halothane. Blood
was collected into heparinised tubes, and plasma was separated by
centrifugation (2000 g, 20min, 41C). Tissues (liver, tumour,
small intestinal mucosa) were collected, the latter after extensive
washing (PBS) to remove intestinal content, and stored at  801C
until analysis. Plasma and tissue samples were thawed at room
temperature. Aliquots of cellular supernatant or plasma (0.1ml)
were vortex-mixed with internal standard, and analytes were
extracted into an equal volume of acetone/acetic acid (0.1 M). The
mixture was vortexed twice (1min each) and centrifuged (300 g,
20min). An aliquot of the supernatant (0.2ml) was mixed with
water (0.1ml). After centrifugation (5min), a sample (50 or 100ml)
was injected onto the HPLC column. Thawed tissue was washed
with water to remove surface blood; excess water was blotted with
filter paper. An aliquot (100–200mg) of wet tissue was weighed,
suspended in water (0.4ml) and homogenised (manual glass
homogeniser from Jencons, Leighton Buzzard, UK). Samples of
plasma and livers from each mouse were analysed in duplicate,
tumour tissue was pooled, and analysis of analyte in tumour was
conducted in triplicate. The homogenate was extracted with an
equal volume of acetone/acetic acid (0.1 M), as described for
cellular incubates and plasma. Chemical analysis was conducted
using an HPLC system consisting of a ProStar pump (Model 230)
coupled with a ProStar Model 410 auto-sampler and a ProStar
Model 310 UV-Vis detector, all from Varian (Varian Analytical
Instruments, California, USA). Separation was achieved on a
ThermoHypersil BDS C18 column (250 4.6mm
2, particle size
5mm, ThermoHypersil-Keystone, Cheshire, UK) using ammonium
acetate buffer (0.1 M, pH 5.1) with methanol (52%) and EDTA
(0.27mM) as the isocratic mobile phase. The flow-rate was
1mlmin
 1, the detection wavelength 355nm. Development and
validation of the HPLC analysis of tricin in the biomatrix have
been reported before (Cai et al, 2003).
Statistical evaluation
Data shown in the results section and the figures are expressed as
means7s.d. Routine statistical evaluation with Minitab (v 13)
software used either the general linear model ANOVA, with time
and treatment as categorical variables followed by Fisher’s least-
square difference test, or one-way ANOVA following which
statistical significance (Po0.05) was established by post hoc
Tukey’s pairwise comparison.
RESULTS
Reversibility of cell growth inhibition
Initially, the breast cell growth-inhibitory properties of tricin were
re-investigated in malignant MDA-MB-468 and nonmalignant, but
transformed, HBL-100 cells. Cells were treated with tricin (0.1–
50mM) for periods of up to 168h, after which cells were counted.
Tricin inhibited growth in a concentration- and time-dependent
manner (Figure 2). The IC50 values determined at 168h for MDA-
MB-468 and HBL-100 cells were 0.7 and 21mM, respectively,
suggesting that tricin was 30 times more potent as a growth
inhibitor in MDA-MB-468 than in HBL-100 cells, which is
consistent with results reported earlier (Hudson et al, 2000).
In order to determine whether growth inhibition elicited by
tricin was transient or permanent, the ability of cells to recover was
determined following treatment of cells with tricin for 72h,
followed by exposure to tricin-free medium for another 96h
(‘recovery conditions’), while control cells were incubated without
tricin for the whole 168h period. For comparison, cultures were
included in which cells were exposed to tricin for 168h. After
exposure to tricin 1–10mM for 72h, followed by the recovery
period, numbers of MDA-MB 468 cells were 25–28% of untreated
controls. Only 8% overcame the inhibitory effect of exposure to
20mM tricin. Cells, which had been exposed to 40mM tricin, did not
recuperate at all from tricin-induced growth arrest (Figure 3). In
contrast, when tricin was removed from the medium of HBL-100
cells, most cells recovered and grew at a rate close to that of control
cultures.
Effect of tricin on cell cycle distribution
The hypothesis was tested that the growth-inhibitory effect of
tricin is the result of a perturbation of the cell cycle, possibly
leading to programmed cell death. The effect of tricin on MDA-
MB-468 and HBL-100 cell cycle distribution and level of apoptosis
was explored. Tricin induced a G2/M phase arrest in asynchronous
MDA-MB-468 cells, evident at concentrations X5mM (Figure 4).
The tricin-mediated increase in percentage of cells in G2/M was
dose- and time-dependent and largely attributable to depletion of
cells in G1, with a decrease in S phase cells at the 72 and 96h time
points. In contrast, treatment of HBL-100 cells with tricin using the
same concentration range and treatment times did not alter cell
cycle distribution significantly (Figure 4).
Flow cytometric characterisation of phosphatidyl serine ex-
ternalisation using FITC-conjugated annexin V and PI staining did
not reveal any difference in detectable numbers of apoptotic cells
between tricin-exposed and unexposed cells in either cell line at
times from 24 up to 96h. At 168h there was a slight increase (10%)
in combined numbers of apoptotic and necrotic cells in MDA-MB-
468 cells treated with 40mM compared with control cells, but not in
the HBL-100 cell line (data not shown).
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Tricin is an agent for which hardly any pharmaceutical information
exists. To permit interpretation of the effects on cell growth
described above, we established whether it is stable under cell
culture conditions. Tricin was analysed by HPLC in extracts of cells
and culture medium after treatment for 72h. Tricin was detectable
in cultures when added at 5mM or more. Consistently, between 94%
(cultures with 5mM) and 71% (at 40mM) of tricin added to the
medium was recovered from cultures, irrespective of whether they
contained MDA-MB-468 or HBL-100 cells, suggesting that stability
during the period of cell culture incubation is satisfactory. There
was no product of tricin degradation detected by the HPLC analysis.
Effect of tricin on MDA-MB-468 tumour growth in nude
mice in vivo
In order to investigate whether the growth-inhibitory efficacy of
tricin established in cells in vitro could also be observed in vivo,
athymic nude mice harbouring MDA-MB-468 tumour cells as a
subcutaneous injection received tricin at 0.2% in the diet
(approximately 300mgkg
 1 body weight per day) from 1 week
prior to tumour implantation to the end of the experiment. The
body weight of mice on the tricin-supplemented diet did not differ
from that of control mice, which suggests that tricin at this dose
was easily tolerated. The tumours, which grew on the flanks of the
mice, had features of cellular adenocarcinomas, with poor
glandular differentiation. Tumours infiltrated connective tissue,
skeletal muscle or lymphoid tissue. Figure 5 shows that in treated
animals tumours grew at a rate that was slightly impeded
compared to controls; nevertheless, the difference was not
significant. Terminal tumour weights were 0.1270.17g in
untreated and 0.1170.15g in treated animals (n¼12 for each
group). There was no clear histopathological difference in tumour
cytology between the treated and control groups.
Levels of tricin in mice in vivo
The distribution of tricin in the plasma and selected tissues was
determined by HPLC at the end of the experiment, that is, after 9
weeks of dietary consumption of tricin (0.2%). Steady-state
concentrations of tricin in the plasma, liver, small intestinalucosa
and tumour tissue were 0.1370.16mM and 0.8070.36, 62.6730.5
and 0.1170.13nmolg
 1, respectively (n¼12 for plasma, small
intestine mucosa and liver and n¼3 for tumour). These results
suggest that tumour levels of tricin achieved by dietary consump-
tion were insufficient to elicit tumour growth inhibition, as they
were only a seventh of the IC50 established when MDA-MB-468
cells were grown in vitro (vide supra).
Effect of preincubation of MDA-MB-468 cells with tricin on
tumour growth in vivo
In the light of the lack of efficacy of tricin when administered with
the diet at 0.2%, the tricin concentration required to compromise
the development of the MDA-MB-468 tumour in an in vitro–in
C
e
l
l
 
n
u
m
b
e
r
 
(
×
1
0
4
)
 
Time of incubation (h)
0
0 24 72 120 168 0 24 72 120 168
20
40
60
80
Control
0.2 M 
10 M 
25 M 
50 M  0.6 M 
1.0 M 
MDA-MB-468 HBL-100
Figure 2 Effect of tricin on the growth of MDA-MB-468 and HBL-100 cells. Concentrations of 0.2–10mM were used with MDA-MB-468 cells, and 1–
50mM with HBL100 cells. Cell numbers are the mean of triplicate samples. Pooled standard deviations are shown only in the case of numbers of untreated
cells. Results are the mean of n¼6, the values obtained at 120h or later for tricin concentration of 0.6mM and higher in the MDA-MB-468 cells or of 10mM
and higher in the HBL-100 cells were significantly different from the numbers of control cells (Po0.05) as determined by one-way ANOVA followed by
Tukey’s post hoc test. For details of cell culture and tricin treatment see Materials and Methods.
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Figure 3 Recovery of MDA-MB-468 and HBL-100 cells following
treatment with tricin. Cells were treated with tricin for 168h (open bars),
or treated with tricin for 72h and then kept for 96h in medium omitting
tricin (‘recovery’, closed bars). Cells cultured without tricin for the whole of
the 168h incubation period were included as controls. Values reflect the
increase in cell number under the respective conditions at the end of the
experiment over cell numbers observed at 72h, and they are expressed as
percentage of the fold increase in control cells from which tricin was
omitted for the whole 168h. Results are the mean7s.d. of n¼3–5, the
pooled s.d. was 12.7 and 12.5% of the mean for MDA-MB-468 and HBL-
100 cells, respectively. Star indicates that cell numbers were significantly
different from those in control cultures (Po0.05) as determined by the
ANOVA general linear model followed by Fisher’s least significant
difference evaluation. For further details of cell culture and tricin treatment
see Materials and Methods.
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svivo bioassay setting was investigated. Under these conditions cells
are exposed to tricin in vitro and subsequently transplanted into
the animal. MDA-MB-468 cells were incubated with tricin, or with
vehicle only, for 3 days, and then implanted into the flank of mice.
The tricin concentrations employed in this experiment were 0.11,
1.1 and 11mM, that is, levels that were identical with, or ten and a
hundred times greater than those concentrations to which MDA-
MB-468 tumour had been exposed under in vivo condition when
animals received tricin with the diet. Cells were still capable of
proliferation when incubated with such concentrations of tricin in
vitro as shown in Figure 2 (compare cell numbers at 72 and 168h),
and also showed some recovery of growth rate when tricin was
removed from the culture medium following a 72h incubation
(Figure 3). Figure 6 shows that tumour volumes in mice, that had
been inoculated with cells after incubation with 0.11 or 1.1mM
tricin, were similar to those of tumours in mice, which had
received cells incubated with the vehicle only. Nevertheless, mean
tumour volume in animals bearing cells, which had been incubated
with 11mM tricin, was less than a third of that in mice which had
received control cells (Figure 6). The variation in tumour size in
each of the four experimental groups of mice was substantial (see
legend to Figure 6), an observation which is consistent with
previous experience in this laboratory with MDA-MB-468 cells
grown in the nude mouse model when used in the evaluation of
other putative chemopreventive agents. The large variability
confounded the establishment of statistical significance when
tumour volumes were compared using either one-way ANOVA,
Student’s t-test or Mann–Whitney nonparametric test as statistical
vehicle, irrespective of whether mice that failed to develop tumours
were included or excluded. As some of the tumour size data were
not normally distributed because of skewing consequent to very
large or totally absent tumours, descriptive statistical evaluation of
the data was performed yielding median values and interquartile
ranges (Table 1). Consistent with the results obtained when
tumour volume was measured, terminal tumour weights in mice
which had been inoculated with unexposed cells or with cells
previously exposed to tricin at 0.11, 1.1 or 11mM were
0.08370.052, 0.09570.061, 0.07170.084 and 0.03770.084g,
respectively. Analogous with the dietary intervention study, there
was no histopathological difference in cytology between tumours
MDA-MB-468 HBL-100
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24   38.6±4.6 41.0±7.7 22.4±3.2
43.6±4.4 31.9±2.3 24.6±3.1
35.8±2.6 41.4±3.8 22.7±2.3
35.8±2.1 42.0±0.2 22.1±2.0
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Figure 4 Effect of tricin on distribution of MDA-MB-468 and HBL-100 cells in the G1 (open bars), S (grey bars) and G2/M (closed bars) phases of the cell
cycle. Cells were analysed by flow cytometry following treatment with tricin or vehicle control for 24, 48, 72 or 96h and staining with PI. Values (mean of
n¼4) reflect the change in percentage cell number under the respective conditions from the number in that phase in control cultures at each time point.
The s.d. was between 0.64 and 8.7% of the mean. The tabular inserts show cell cycle distribution observed in control cultures expressed as percentage of
total cells (100%), and the values are the mean7s.d. of n¼4. Star indicates that cell cycle distribution was significantly different from that observed for
control cultures (Po0.05, determined by the ANOVA general linear model followed by Fisher’s least significant difference). For details of cell culture, tricin
treatment and flow cytometry see Materials and Methods.
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soriginating from mice, which harboured vehicle-exposed or tricin-
exposed cells.
DISCUSSION
The results outlined above allow the following four new insights
into the pharmacology of tricin in breast cancer cells: (i) tricin
arrests the growth of malignant MDA-MB-468 cells in an
irreversible manner without exerting such an effect on nonmalig-
nant HBL-100 cells; (ii) tricin arrests MDA-MB-468 cells in the G2/
M phase of the cell cycle, but this inhibition is not the prelude to
induction of apoptosis; (iii) the growth-inhibitory potential of
tricin translates into antitumour efficacy in an in vitro–in vivo
bioassay system, in which mice are inoculated with MDA-MB-468
cells that have been previously exposed to tricin; (iv) consumption
of tricin with the diet at 0.2% is insufficient to elicit an antitumour
effect in mice bearing the MDA-MB-468 tumour.
The involvement of G2/M phase arrest in the inhibition of breast
cancer cell growth by tricin implicates a number of protein
regulators of cell-cycle transition at G2/M checkpoints as potential
candidate targets with which tricin might engage in causing growth
arrest. Among these molecules are p34
cdc2, Wee1, cdc25 and p21
cip.
p34
cdc2 is a cyclin-dependent kinase, which in association with
cyclin B1 controls transition of the cell from G2 into M phase. The
kinases Wee1 and cdc25 inhibit and activate, respectively, the
p34
cdc2–cyclin B1 complex. p21
cip is a cyclin-dependent kinase
inhibitor, which associates with the p34
cdc2–cyclin B1 complex and
promotes a block in both G2 and G1 phases. Apigenin (40,5,7-
trihydroxyflavone) is chemically closely related to tricin, its
chemical structure differing from that of tricin only in that it
lacks the two O-methyl moieties in positions 30 and 50 of ring B in
tricin. Apigenin has also been shown to arrest MDA-MB-468 cells
in G2/M phase, and this effect was linked to decreased expression
of cell cycle proteins CDK1, CDK4, cyclins B1,D 1 and A (Yin et al,
2001). Future studies will help to discover whether tricin interferes
with cell-cycle regulatory proteins in a manner analogous to
apigenin. The robust ability of tricin to confound breast cell
proliferation hints at its potential as a chemotherapeutic agent,
which might be a topic worthy of further elucidation, perhaps in
judicious combination with a cellular signalling inhibitor.
The IC50 for MDA-MB-468 cell growth inhibition by tricin under
conditions of cell culture for 168h was 0.7mM. Similarly,
incubation with 1mM tricin for 72h sufficed to cause partially
irreversible growth arrest when cells were allowed to grow in vitro
subsequent to tricin removal. In contrast, in the in vitro–in vivo
bioassay system, incubation of cells with 10mM tricin for 72h prior
to implantation into mice was required to afford a robust decrease
in subsequent tumour development in vivo, whereas incubation
with 1mM tricin failed to cause a marked decrease in tumour
volume when compared to tumours in control mice. It seems that
the murine subcutaneous flank environment, unlike the in vitro
cell culture medium, provides factors that can overcome the partial
disturbance by 1mM tricin of the mechanistic cascade regulating
tumour cell proliferation. This difference in tricin concentration
required for tumour growth arrest illustrates a discrepancy in
intrinsic growth potential between cells in culture on the one hand
and cells in the rodent organism in vivo on the other, even without
taking differential tricin exposure characteristics and bioavail-
ability between the two environments into account. For the sake of
comparison, in an in vitro–in vivo bioassay similar to the one
employed here with tricin, exposure of MDA-MB-468 cells to the
isoflavone genistein at 30mM for 6 days prior to inoculation of cells
into nude mice, abrogated tumour development completely,
whereas incubation for 2 days affected tumour growth in vivo
only ephemerally (Constantinou et al, 1998).
The result of the analysis of tricin in blood and tissues of mice,
which had received the tricin-containing diet, intimates that the
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Figure 5 Effect of dietary supplementation with tricin (0.2%, circles) or
control diet only (RM1, squares) on the growth of MDA-MB-468 tumour
cells implanted in female MF1 nude mice. Tricin was added to the diet from
1 week prior to tumour implantation, continuing until termination of the
experiment. Cells (10
7) were implanted subcutaneously into the right hind
flank. The results are the mean7s.d. for 12 mice. For details of cell culture,
tumour inoculation and treatment see Materials and Methods.
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Figure 6 Effect of exposure in vitro of MDA-MB-468 tumour cells to
tricin (0.11, 1.1 or 11mM) or to vehicle only on cell growth in vivo after
implantation of cells into female nude MF-1 mice. In this in vitro–in vivo
bioassay experiment, cells were incubated with tricin for 3 days, after which
they were washed and implanted into the right hind flank of mice. Values
are the mean for six mice. The s.d. values, which have been omitted for the
sake of clarity, were consistently between 90 and 130% of the mean. For
details of cell culture, cell incubation and tumour inoculation see Materials
and Methods.
Table 1 Median values and interquartile ranges of tumour volumes in
mice harboring MDA-MB-468 tumour cells previously exposed to tricin in
vitro
a
Week of tumour
development
Cell pretreatment
with tricin (lM)
Median value
(mm
3)
Interquartile
range (mm
3)
4 0 15 93
11 2 17
6 0 45 173
11 9 60
8 0 78 358
11 8 88
aCells were incubated for 72h prior to inoculation into mice. For details of bioassay
procedure, see Materials and Methods.
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ssystemic bioavailability of tricin might be low when administered
in this manner. Dietary administration led to comparable
concentrations in plasma and tumour, in the 10
 10–10
 9mole
per ml or g range, which is clearly subefficacious when compared
to concentrations required for growth inhibition in vitro. Thus, it
is not surprising that supplementation of the diet with tricin failed
to affect tumour development. Nevertheless, steady-state levels of
tricin in the liver and gastrointestinal mucosa were six- and 450-
fold, respectively, higher than the levels determined in the plasma,
which suggests that it would be appropriate to explore the activity
of dietary tricin in the prevention of hepatic and – in particular –
gastrointestinal malignancies in rodents. Consistent with this
notion, human derived SW480 colon cancer cells were found to be
sensitive to the growth-arresting properties of tricin with an IC50 of
16mM (Hudson et al, 2000). As a tri-phenol tricin is conceivably a
good substrate of conjugating enzymes, and efficient biotransfor-
mation may curtail its boavailibility. Preliminary evidence suggests
that tricin does indeed undergo metabolic sulphation in the
gastrointestinal tract and glucuronidation in mouse liver homo-
genate fortified with UDP glucuronyl transferase, yielding in each
case two products identifiable by HPLC (Cai, Steward and Gescher,
unpublished).
Good efficacy, lack of toxicity and reasonable bioavailability are
three crucial prerequisites for the advancement of flavonoids into
clinical development as cancer chemopreventive agents. In terms
of the stage of clinical development of naturally occurring
flavonoid aglycones, genistein is probably the molecule furthest
advanced, as it is currently under phase II clinical evaluation for
prevention of recurrent localised prostate cancer subsequent to
radical prostatectomy (see website http://www.cancer.gov/clinical-
trials). Genistein has shown chemopreventive activity in several
rodent models of carcinogenesis including those of the breast
(Lamartiniere et al, 1995a,b; Constantinou et al, 1996), but it is
characterised by a very short plasma half-life in rodents (Supko
and Malspeis, 1995). As far as the toxicity of genistein is
concerned, its ability to induce site-specific DNA cleavage in the
breakpoint cluster region of the mixed lineage leukaemia (MLL)
gene in vivo (Strick et al, 2000) has raised concerns as to the
suitability of its widespread use in humans. This property, which
genistein shares with apigenin and quercetin, is considered
germane to the aetiology of childhood leukaemia, in which dietary
Soya as a source of genistein has been implicated. Quercetin is an
example of a flavonoid, the early clinical development of which has
been aborted because of poor bioavailability (Ferry et al, 1996).
Compared to genistein and quercetin, tricin lacks such toxicolo-
gical features, since it has been shown to be incapable of inducing
the MLL gene cleavage (Borkhard, Mann, Hudson and Gescher,
unpublished). Furthermore, three recent studies commissioned by
the US National Cancer Institute have established that tricin lacks
mutagenic properties as reflected by its complete inability to
induce either chromosomal aberrations in Chinese hamster ovary
cells (‘Evaluation of tricin in the Chinese hamster ovary
chromosome aberration assay’ SRI International technical report,
2003, unpublished), micronuclei in bone marrow erythrocytes of
Swiss-Webster mice (‘Evaluation of tricin in the mouse bone
marrow micronucleus assay’, SRI International technical report,
2003, unpublished), or revertant colonies in the Salmonella
Escherichia coli assay (‘Evaluation of tricin in the Salmonella—E.
coli/microsome preincubation assay, SRI International technical
report, 2004, unpublished). The work described here illustrates the
considerable growth-inhibitory potency of tricin in MDA-MB-468
cells, but it does not support the notion that tricin as such is a
promising candidate for breast cancer chemoprevention. The
translation of the growth-inhibitory property into activity in
rodent models of breast carcinogenesis in vivo may require
pharmaceutical optimisation of the formulation of tricin or
suitable prodrug development to increase its bioavailability in
the target tissue. The high level of tricin found in the
gastrointestinal tract after dietary intake renders exploration of
its ability to prevent colorectal carcinogenesis propitious. Such
attempts are probably worthwhile in the light of the emerging
favourable pharmacological profile of tricin, which may ultimately
render this flavone a suitable candidate for clinical evaluation.
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